[1]World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva: WHO, 2009.[2] 中华人民共和国卫生部编.全国结核病耐药性基线调查报告(2007—2008)[M].北京:人民卫生出版社,2010,24.[3] Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries[J]. JAMA, 2000, 283(19):2537-2545.[4] Ohkado A, Aguiman L, Adlawan S, Baring E, Quirante O, Suchi M, Endo, S, Fujiki A, Mori T. Tuberculosis drug-resistance and treatment outcomes under DOTS settings in large city in the Philippines[J]. Int J Tuberc Lung Dis, 2006,10:283-289.[5] Arevalo M, Solera J, Cebrian D, Bartolome J, Robles P. Risk factors associated with drug-resistantMycobacterium tuberculosisin Castilla-la-Mancha (Spain)[J]. Eur Respir J, 1996, 9(2):274-278.[6] 王国杰,徐吉英,王国斌, 甄新安, 高三友, 杜长梅.河南省结核病耐药水平对全程督导短程化疗效果的影响[J].中华结核和呼吸杂志,2006, 29: 527-530.[7] 孟祥红,匡铁吉,杨彩娥,董梅.107例耐多药结核病耐药性分析[J].医学临床研究,2006,23(2):326-327. |